Safety
hypothyroidism, proteinuria
ADVERSE EVENTS, HYPOTHYROIDISM, ADVERSE EVENT
The median duration of treatment was 7.0 months (range, 0.7–15.2) for combination therapy. At least one TRAE of any grade occurred in 20 patients (95.2%), the most common of which were hypothyroidism (eight patients, 38.1%), increased aspartate aminotransferase (AST; seven patients, 33.3%) and proteinuria (seven patients, 33.3%; Table Summary of treatment‐related adverse events (intent‐to‐treat population; 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; TRAE, treatment‐related adverse event.